Detalhe da pesquisa
1.
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Lancet Oncol
; 22(4): 512-524, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33721562
2.
Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma.
Blood Adv
; 6(2): 590-599, 2022 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34644372
3.
Requirement for PLCγ2 in IL-3 and GM-CSF-stimulated MEK/ERK phosphorylation in murine and human hematopoietic stem/progenitor cells.
J Cell Physiol
; 226(7): 1780-92, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21506110